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Recent advances in endovascular thrombectomy have enabled the histopathologic analysis of fresh 
thrombi in patients with acute stroke. Histologic analysis has shown that the thrombus composition 
is very heterogeneous between patients. However, the distribution pattern of each thrombus 
component often differs between patients with cardiac thrombi and those with arterial thrombi, 
and the efficacy of endovascular thrombectomy is different according to the thrombus 
composition. Furthermore, the thrombus age is related to the efficacy of reperfusion therapy. 
Recent studies have shown that neutrophils and neutrophil extracellular traps contribute to 
thrombus formation and resistance to reperfusion therapy. Histologic features of thrombi in 
patients with stroke may provide some clues to stroke etiology, which is helpful for determining the 
strategy of stroke prevention. Research on thrombus may also be helpful for improving reperfusion 
therapy, including the development of new thrombolytic agents.
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Introduction
Ischemic stroke is caused by cerebral artery occlusion. Throm-
bus is the primary cause of arterial occlusion and the main tar-
get of acute and preventive treatment in stroke. Thrombus is 
the end-product of thrombosis caused by diverse etiologies. In 
this sense, knowledge on thrombus may provide some insights 
into the mechanism of thrombosis and further ideas on the 
treatment of stroke.
Before mechanical endovascular era, the examination of 
thrombus was only possible postmortem and in very few pa-
tients. As such, knowledge on the characteristics of thrombus 
in stroke has been based on a conceptual idea of thrombus 
formation in different stroke etiologies. Traditional teaching on 
thrombus involved a simple categorization based on the domi-
nant composition: red, white, and mixed; platelet-rich, fibrin-
rich, and erythrocyte-rich. Preventive treatment was also based 
on a simplistic and conceptual idea of thrombus formation 
that a thrombus of the arterial origin is platelet-rich and that 
of the cardiac origin, such as atrial fibrillation, is erythrocyte/
fibrin-rich. As a result, antiplatelet agents have been used for 
stroke prevention in those with suspected arterial etiology and 
anticoagulants in those with suspected cardiac etiology. How-
ever, the antemortem analysis of fresh thrombi is now possible 
in acute stroke patients. 
The successful introduction of endovascular thrombectomy 
has improved the clinical outcomes of stroke patients.1 Moreover, 
it has markedly changed the care system and treatment strategy 
for acute stroke; these improvements include the extension of 
the therapeutic time window, use of advanced imaging for pa-
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tient selection, development of new thrombectomy techniques, 
prehospital diagnosis and triage of patients, and launching of 
the concept of a thrombectomy-capable stroke center.2-5
Recently, fresh thrombi have become obtainable during en-
dovascular thrombectomy, and this availability has increased 
bench side research on thrombi. Earlier studies have focused 
on thrombus composition according to different stroke etiolo-
gies, as well as the association between imaging findings and 
thrombus histology. More recent studies have investigated 
treatment-related issues based on thrombus histology. The im-
aging of thrombus and correlation of imaging with the histo-
pathology of thrombus in stroke have been extensively re-
viewed previously.6,7 Additionally, a consensus statement paper 
was also published on the analysis of thrombi in acute stroke.8
We herein review available literature on thrombus in stroke, 
including the thrombus composition and various stroke etiolo-
gies; leukocytes and neutrophil extracellular traps (NETs), 
which have recently emerged as a key player in thrombus for-
mation; thrombus histology and the efficacy of reperfusion 
therapy; and pathophysiologic and therapeutic perspectives 
based on thrombus research. 
Thrombus composition and stroke 
etiology
The characteristics of thrombus may somehow represent the 
pathophysiologic mechanism of thrombus formation. Several 
studies have attempted to determine stroke etiology based on 
histologic examinations of thrombi obtained during endovas-
cular thrombectomy. 
Determined etiology
Traditional teaching states that a thrombus of the cardiac origin 
is erythrocyte/fibrin-dominant due to a slow flow in the cardiac 
chamber, whereas that of the arterial origin is platelet-domi-
nant due to a high flow at the stenotic arterial segments. Earlier 
studies have examined thrombi using hematoxylin and eosin 
(H&E) staining. They showed that thrombi retrieved in stroke 
patients are heterogeneous and diverse, and failed to identify 
any difference in the histological features between thrombi of 
the cardiac origin and those of the arterial origin.9,10 Subsequent 
studies used histochemical and/or immunohistochemical stain-
ing to better identify each thrombus component. Most studies 
have focused on relative amounts of each thrombus component 
according to the stroke etiology. In a small case series, there 
were controversies in the dominant composition of thrombi be-
tween the cardiac and arterial thrombi.11-13 However, more re-
cent studies with larger samples showed that erythrocyte domi-
nancy was seen in the arterial or noncardiac thrombi and fibrin/
platelet dominancy in the cardiac thrombi (Table 1).14-16 
Histologic findings of fresh thrombi obtained during me-
chanical thrombectomy suggest that the thrombus composi-
tion in large vessel occlusion in stroke is somewhat different 
from traditional teaching; that is, thrombi of both arterial and 
cardiac origins show a mixed red-white pattern, but erythro-
cyte dominancy is more frequent in arterial thrombi than in 
cardiac thrombi (Table 1).9-14,16-19
Leukocytes are often present in thrombus. leukocytes identi-
fied by H&E staining are more dominant in cardiac throm-
bi.13,14,17,19 However, in studies that assessed T-cells and mono-
cytes based on immunohistochemistry, the majority of T-cells 
and monocytes were detected in a random distribution in 
erythrocyte-rich areas and red clots.20 The number of T-cells 
was significantly higher in thrombi from the atherothrombotic 
group than in those due to other causes or cardioembolism 
groups.21 Leukocyte dominancy may partly depend on the 
thrombus age, in that older thrombi have more neutrophils 
than fresh thrombi.22 Thrombi with a high leukocyte fraction 
were related to more organized thrombi of the cardioembolic 
origin.17 In addition, leukocyte infiltration into the thrombus 
shifted from neutrophils to monocytes/macrophages in a ve-
nous thrombosis model in mice.23
Cryptogenic and other etiologies 
A few studies have evaluated the thrombus composition in pa-
tients with cryptogenic etiology. There were no significant dif-
ferences in the proportion of thrombus components between 
patients with an undetermined etiology and those with a car-
dioembolism or large artery atherosclerosis.17 However, other 
studies showed that similar histologic features between cryp-
togenic and cardioembolic stroke patients.13,14,19 Uncovered 
cardiac sources have been suggested as the main etiology of 
cryptogenic stroke.13 Although further studies are necessary, 
histologic findings of thrombi support the current understand-
ing of the cryptogenic stroke etiology. 
Some patients with active cancer develop stroke.24 A recent 
study assessed thrombus composition using immunohisto-
chemistry in patients with active cancer who underwent endo-
vascular thrombectomy.25 Thrombus composition was com-
pared between patients with active cancer, those with inactive 
cancer, and those without cancer. Patients with active cancer 
showed a higher platelet fraction and a lower erythrocyte frac-
tion than those with inactive cancer or those without cancer. 
Patients with vegetation in the cardiac valve (nonbacterial 
thrombotic endocarditis [NBTE]) had very high platelet and low 
erythrocyte fractions.25 Similar findings have been shown in 
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postmortem pathologic studies of vegetation in NBTE, which 
comprises a platelet mass with interwoven fibrin.26,27 
The findings of high platelet and low erythrocyte fractions 
were also shown in patients with cryptogenic stroke etiology 
among those with active cancer.25 Stroke etiology is crypto-
genic in approximately half of stroke patients with active can-
cer.28 In a large autopsy study of patients with stroke and can-
cer, NBTE was the most common etiology, comprising 51.3%.29 
Altogether, these findings indicate that thrombus in cancer-as-
sociated NBTE is platelet-rich. 
Information on thrombus histology in stroke patients with 
rare causes remains insufficient. In one study, three patients 
with arterial dissection showed mixed but erythrocyte-domi-
nant thrombi.11 Further studies with larger sample sizes and di-
verse etiologies are necessary to better understand thrombus 
histology in stroke with different causes. 
Leukocytes and neutrophil extracellular traps
Traditional teaching on thrombus formation has focused on 
platelets, erythrocytes, and fibrins. However, leukocytes are im-
portant players in thrombosis. Recent studies have demon-
strated the role of neutrophils and NETs in thrombus forma-
tion.30 NETs are a web-like structure of deoxyribonucleic acid 
(DNA) fibers comprising histones and granules that are released 
by activated neutrophils (Figure 1). The primary role of NETs is 
to ensnare and kill pathogens. Recently, NETs have been shown 
to play an important role in arterial and venous thrombosis.31,32 
Together with the fibrin meshwork, NETs form a scaffold of 
thrombus. NETs are also actively involved in thrombosis by 
their interaction with platelets, erythrocytes, and platelet ad-
hesion molecules such as fibrinogen, von Willebrand factor, 
and fibronectin.32 
 Neutrophils and NETs are found in thrombi retrieved during 
mechanical thrombectomy, and they are frequently colocalized 
(Figure 2). On immunohistochemistry, NETs show different fea-
tures among thrombi of stroke patients. They are seen as being 
confined within cells, in either filopodia-like or web-like struc-
tures (Figure 3). These features may represent the temporal 
Table 1. Thrombus composition and etiology of stroke
Study
Patient
no.
Device Staining method
Analysis  
(quantitation)
RBC-dominancy
Fibrin/fibrin-platelet-
dominancy
Leukocytes
Marder et al. 
(2006)9
25 Merci H&E Feature detection 
analysis
No differences  
between etiologies
No differences  
between etiologies
Liebeskind et al. 
(2011)10
50 Merci H&E Semi-automated No differences  
between etiologies
No differences  
between etiologies
Sato et al. (2012)18 17 Autopsy IHC (fibit for fibrin, plate-
let glycoprotein IIbIIIa 
for platelets, glyco-
phorin A for RBC
Semi-automated Cardiac No differences  
between etiologies
Niesten et al. 
(2014)11
22 Merci, Trevo, 
solitaire
H&E, Mallory’s phospho-
tungstic acid-hematox-
ylin (fibrin)
IHC (glycophorin A for 
RBC, CD31 for platelets)
Consensus Arterial dissection No differences  
between etiologies
Kim et al. (2015)12 37 Solitaire,  
aspiration
H&E 
IHC (CD61 for platelets)
Semi-automated Cardiac Arterial (fibrin)
No difference (platelet)
No difference
Ahn et al. (2016)13 32 Aspiration H&E, MSB, IHC (CD42b 
for platelets)
Semi-automated Arterial Cardiac (fibrin)
Cryptogenic
Cardiac
Boeckh-Behrens et 
al. (2016)14
137 Not specified H&E, Elastica van Gieson Semi-automated Noncardiac Cardiac (fibrin-platelet)
Cryptogenic
Cardiac
Boeckh-Behrens et 
al. (2016)17
34 Solitaire,  
Trevo,  
Penumbra 
Pulse
H&E, Elastica van Gieson Semi-automated ND ND Cardiac
Sporns et al. 
(2017)19
187 pRESet stent  
retriever
H&E, Elastica van Gieson, 
Prussian blue
IHC (CD3, CD20, CD68)
Semi-automated Noncardiac Cardiac (fibrin)
Cryptogenic
Cardiac
Maekawa et al. 
(2018)16
79 Solitaire,  
Trevo, Revive, 
Penumbra
HE Semi-automated Arterial 
Cryptogenic
Cardiac (fibrin) No difference
RBC, red blood cell; H&E, hematoxylin and eosin; IHC, immunohistochemistry; MSB, Martius scarlet blue; ND, no description.
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process of NET formation. NETs are at first formed within acti-
vated neutrophils, then show filopodia-like structure as they are 
released from neutrophils, and finally form a web-like structure 
(Figure 1). The activity of NETs increases as the number of neu-
trophils increases,25 which suggests that web formation by NETs 
is facilitated as more neutrophils infiltrate into thrombus. 
It is uncertain whether the proportion of NETs is different 
among different stroke etiologies. While one study has shown 
Figure 1. An illustration showing the process of neutrophil extracellular trap (NET) formation. NETs are formed within activated neutrophils, and then released 
from neutrophils. Released NETs form a web-like structure, which plays a role as a scaffold of thrombus. NETs also actively interact with platelets and erythro-
cytes to form thrombus.
Web formation
Erythrocyte
Platelet
NET formation and release
Neutrophil activation
chromatin decondensation
Neutrophil
Figure 2. Representative immunohistochemistry images of the human thrombus outlining (A) neutrophils (anti-myeloperoxidase) and (B) neutrophil extracel-
lular traps (anti-histone H3). Areas expressing neutrophils are overlapped with those expressing neutrophil extracellular traps. Positive signals to primary anti-
bodies were developed using 3,3ʹ-diaminobenzidine, and are seen as areas of brown staining (×400). 
Neutrophil Neutrophil extracellular traps
A B
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that NETs are more abundant in cardiogenic thrombi than in 
thrombi due to other causes,22 there was no association be-
tween NET content and stroke etiology in another study.33 Be-
cause older thrombi have more neutrophils and NETs than 
fresh thrombi,22 the thrombus age may be closely related to the 
amount of NET content in thrombi.
Thrombus age and stroke etiology
The thrombus age may differ according to the stroke etiology. 
Embolization may occur sooner or later after thrombus forma-
tion at the original site. Thrombus are often classified as fresh 
or lytic and organized according to its age and histologic fea-
tures. A fresh thrombus (<1 day) is composed of layered pat-
terns of platelets, fibrin, erythrocytes, and intact granulocytes, 
a lytic thrombus (1 to 5 days) is characterized by areas of colli-
quation necrosis and karyorrhexis of granulocytes, and an or-
ganized thrombus (>5 days) shows ingrowth of smooth muscle 
cells, with or without depositions of connective tissue and 
capillary vessel ingrowth.34
In a study that assessed thrombus as fresh, lytic, or orga-
nized, no significant differences were found in the thrombus 
age between the different subtypes of stroke.11 Another study 
assessed the thrombus age based on leukocyte morphology 
and demonstrated that fresh or lytic forms of leukocytes were 
found in arterial thrombi, whereas most cardiac thrombi 
showed organized forms.13 The infiltration of leukocytes in-
creases as the thrombus matures. When considering that leu-
kocytes are more dominant in cardiac thrombus than in arterial 
thrombus, aged forms of thrombus may be more common in 
cardiac thrombi.
Pathophysiologic speculations on the 
mechanism of thrombus formation via 
histologic assessment of thrombus
The distribution pattern of thrombus components may be as-
sociated with hemodynamics, blood flow, shear, and turbulence 
at the site of thrombus formation. A few studies have assessed 
the distribution pattern of thrombus components and com-
pared it between different stroke etiologies. In an earlier study 
based on H&E staining, many patients (17/25, 75%) showed a 
pattern of layers or serpentine showing fibrin/platelet bands 
interspersed with accumulations of nucleated cells and eryth-
rocyte-rich accumulations. However, there was no prevalence 
of a specific etiology.9 In another study using immunohisto-
chemical staining for platelets, some differences were found 
between arterial and cardiac thrombi: the arterial thrombi 
commonly showed platelets located at the edge or periphery of 
the thrombus with erythrocytes masses in the center of the 
thrombi, whereas cardiac thrombi frequently showed scattered 
aggregations of platelets throughout the thrombi, appearing as 
variegated or clustered spots.13 
Figure 3. Variable features of neutrophil extracellular traps. Immunoreactivity to histone H3 (brown staining), representing neutrophil extracellular traps, is 
seen as (A) cell-like (within cells), (B) filopodia-like, or (C) web-like features. Lower panels are magnifications of the upper panel images (×400).
Web-likeFilopodia-likeCell-like
A B C
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The thrombus often shows a laminated or layered pattern 
microscopically, known as the lines of Zahn. The lines of Zahn 
are characterized by alternating layers of platelets (mixed with 
fibrin) and erythrocytes and form at sites of rapid blood flow, 
including the heart and aorta. Although the lines of Zahn have 
been reported in saphenous venous thrombosis,35 they are less 
apparent in veins or smaller arteries. 
The mechanisms of thrombosis in atrial fibrillation have been 
described in relation to the Virchow’s triad and include an ab-
normal vessel wall (endothelial or endocardial damage), abnor-
mal flow (flow stasis), and abnormal blood constituents (abnor-
malities in coagulation, platelets, and fibrinolysis).36 The contri-
bution of various mechanisms to atrial fibrillation results in 
mixed-type thrombi formation with heterogeneous patterns and 
compositions according to the degree of contribution of each 
mechanism (vessel wall, flow, and blood constituents). However, 
it is likely that many of them show a layered pattern or clustered 
spots of platelet aggregates because thrombi are formed under 
the conditions of rapid and constant blood flow (Figure 4). 
A large arterial thrombus is formed via a process different 
from cardiac thrombus formation. In the large artery, such as 
the internal carotid artery bifurcation, platelet aggregates are 
formed at the stenotic segment as a result of the interaction 
between platelets and various integrins on the endothelium 
and by the action of von Willebrand factor that is activated by 
shear stress.37,38 At the poststenotic segment, large erythrocyte 
masses may be formed by turbulent and slow blood flow. Tis-
sue factor is also released upon the rupture of atherosclerotic 
plaques. The released tissue factor locally forms thrombin, 
which then activates platelets and induces fibrin formation.39 
This process may result in a large erythrocyte mass and periph-
erally located platelets (Figure 3). 
However, histologic findings of thrombi that are retrieved 
during endovascular thrombectomy may not reflect the whole 
mechanism of thrombosis in patients with arterial and cardiac 
thrombi. Thrombi that are subjected to histologic analyses are 
large because the patients have received endovascular treat-
ment due to large artery occlusion; in addition, they were all 
retrievable. Smaller or nonretrievable thrombi might have dif-
ferent histology to that of larger and retrievable thrombi. Fur-
thermore, diverse cardiac diseases cause thromboembolism, 
and thrombus histology may differ among different cardiac 
etiologies. Further studies with larger and more diverse patient 
groups may be necessary to better understand the histologic 
features and related mechanisms of thrombosis.
Thrombi obtained in patients with cancer-associated NBTE 
show very high platelet and low erythrocyte fractions.25,40 This 
suggests that platelets play a key role in the formation of veg-
etation. Tumor cells crosstalk with platelets. Tumor cells acti-
vate platelets and induce platelet aggregation, a process 
known as tumor cell-induced platelet aggregation.41 Tumor 
cells secrete platelet-activating mediators such as adenosine 
Figure 4. (A, B, C) Representative immunohistochemistry images of the human thrombus outlining platelets (anti-CD42b), erythrocytes (anti-glycophorin A), 
and fibrin/fibrinogen (anti-fibrinogen) in a patient with atrial fibrillation (AF) and large artery atherosclerosis (LAA). The staining in the patient with AF shows 
a layered pattern of clustered platelets, whereas that in the patient with LAA shows peripherally located platelets and a large erythrocyte mass (×400).
Platelets
AF
LAA
Fibrin Erythrocytes
A B C
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diphosphate, thromboxane A2, and thrombin.42,43 Histological 
findings and evidence on cancer-platelet interaction indicate 
that platelets activated by tumor cells contribute to the devel-
opment of platelet-rich vegetation.
Thrombus composition and efficacy of 
endovascular thrombectomy
Erythrocytes and fibrin
Several studies have investigated whether the efficacy of en-
dovascular thrombectomy differs according to the thrombus 
composition. In earlier studies, no association was found be-
tween the proportion or dominancy of thrombus components 
and outcomes of mechanical thrombectomy using stent re-
trievers (procedure time, recanalization failure, and poor clini-
cal outcome).12,44 In other studies, erythrocyte-rich thrombi 
were associated with a smaller number of recanalization ma-
neuvers and shorter procedure times,15,16 as well as successful 
recanalization.45,46
In contrast, fibrin-rich thrombi with low erythrocyte frac-
tions were associated with a longer interventional time and 
secondary embolism.15 In a recent study, thrombus fragments 
retrieved in each pass of a device were assessed separately. The 
erythrocyte composition was significantly higher in the throm-
bus retrieved in passes 1 and 2 than that retrieved in passes 3 
or more.47 Furthermore, the fibrin composition was significantly 
lower in thrombus retrieved in passes 1 and 2 than that re-
trieved in passes 3 or more. These findings suggest that the 
erythrocyte-dominant portion of the thrombus was easily re-
trieved, whereas the fibrin-dominant portion was more resis-
tant to retrieval.47 Removal of the thrombus depends on the 
thrombus–vessel interaction.48 Different friction properties be-
tween thrombus components may contribute to different re-
sponse to thrombus retrieval between erythrocyte-rich and fi-
brin-rich thrombi. In experiments using an apparatus with 
gradual tilting, fibrin-dominant clots showed a greater coeffi-
cient of friction than erythrocyte-dominant clots.49 
Leukocytes and neutrophil extracellular traps
Thrombi with a higher percentage of leukocytes or NETs were 
associated with an extended mechanical recanalization time, 
number of device passes, and less favorable recanaliza-
tion.17,33,50 The amount of leukocytes and NETs may be associ-
ated with the thrombus age and degree of thrombus organiza-
tion. As the thrombus is organized, the strength of adherence 
to the vessel wall may increase, making the removal or aspira-
tion of thrombus more difficult.17
Other thrombus components
Calcified thrombi are rarely identified on non-contrast com-
puted tomography (CT) before endovascular thrombectomy. In 
a small case series, stent retriever thrombectomy of calcified 
thromboemboli was associated with poor recanalization and 
an increased risk of periprocedural risk, including vessel perfo-
ration.51 The presence of endothelial cells was not associated 
with poor clinical outcomes.44
Thrombus composition and 
periprocedural complications
Vessel wall injury during endovascular 
thrombectomy
Thrombectomy using stent retrievers has a risk of vessel wall 
injury. This injury may occur during retraction of the stent re-
triever in relation to the radial force of the stent against the 
vessel wall, vascular anatomy, the presence of underlying ste-
nosis, the occurrence of vasospasm, or underlying calcification 
of the vessel wall. Furthermore, vessel wall injury may result in 
arterial dissection, endothelial or intimal denudation and sub-
sequent thrombosis, and vessel perforation.51,52
The occurrence of vessel wall injury was investigated by a 
histological analysis of retrieved thrombi. In a study of 48 
thrombi retrieved by stent retrievers, no subendothelial vessel 
wall structures were found.44 However, in a total of 150 throm-
bi from 101 patients treated with penumbra or stent retrievers, 
vessel wall components (internal elastic lamina) were observed 
in 24 specimens (16%) from 22 patients. Factors associated 
with vessel wall injury were a low proportion of erythrocyte 
components, high frequency of the devices reaching the M2 or 
P2 segment, and a high number of device passages.53 Angio-
graphic and clinical outcomes did not differ between patients 
with thrombi containing vessel wall components and those 
with thrombi without these components. Further studies are 
necessary to determine the clinical significance of vessel wall 
injury during endovascular thrombectomy. 
Thrombus migration/fragmentation
After the removal of thrombus from the primary occlusion site 
by mechanical thrombectomy, distal embolization or fragmen-
tation of the thrombus may occur. Fragmentation or distal em-
bolization may be related to the cohesiveness of the thrombus. 
Distal embolization is more frequent in cases with higher 
amounts of neutrophils within the thrombus, or in fibrin-rich 
thrombi with low erythrocyte fractions.15,50 The fraction of 
erythrocytes was not associated with distal embolization.50
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Thrombus composition in patients 
receiving intravenous thrombolysis
Many patients receive bridging intravenous (IV) tissue plasmin-
ogen activator (tPA) before endovascular thrombectomy. Bridg-
ing tPA treatment before endovascular thrombectomy was as-
sociated with a significantly greater erythrocyte composition 
and lower fibrin composition.47,54,55 The thinning of fibrin layers 
was more common in patients treated with bridging IV tPA.56 
In another study, the histologic characteristics of thrombus did 
not differ between patients who received bridging IV tPA ther-
apy and those who did not.50 Moreover, content of the von 
Willebrand factor was not different between patients who re-
ceived IV tPA and those who did not.57 Theoretically, tPA dis-
solves fibrin within the thrombus; therefore, a relatively lower 
fraction of fibrin is expected in patients who receive bridging 
IV tPA than in those who do not. 
Previous studies have not assessed platelet fraction in pa-
tients receiving bridging tPA. However, activation of fibrinolysis 
by tPA treatment may paradoxically activate platelets.58 Plas-
minogen activator inhibitor-1 and α2-antiplasmin are also re-
leased,59 which, in turn, may produce paradoxical thrombosis 
after tPA treatment in some patients with thrombus resistant 
to tPA. This paradoxical action of tPA is known as a key mech-
anism of reocclusion and rethrombosis after tPA treatment, 
which occurs in 22% to 34% of patients.60-63 In fact, in studies 
that measured the thrombus volume on CT before and immedi-
ately after IV tPA treatment, the thrombus was paradoxically 
enlarged in approximately 20% of patients.64,65 Patients who 
did not respond to IV tPA might have large or tPA-resistant 
thrombi. Thus, the platelet fraction may be higher in patients 
who received bridging IV tPA treatment. This hypothesis is 
partly supported by the very effective lysis of reocclusion fol-
lowing tPA treatment using potent platelet glycoprotein IIb/IIIa 
receptor antagonists.61
When responsiveness to IV tPA was defined as an increase in 
the clot burden score, higher erythrocyte fractions were associ-
ated with better responsiveness to IV tPA.66 
Therapeutic perspectives
Thrombus age and targeting NETs 
Over time, cells and extracellular matrix molecules within the 
thrombus undergo microstructural changes. These changes 
may affect the response to recanalization treatment. Recent 
studies have indicated that leukocytes and NETs are more 
abundant in older thrombus, with older thrombi demonstrating 
more neutrophils and NETs than fresh thrombi.22 In a venous 
thrombosis model in mice, the number of neutrophils was the 
greatest at day 1, which, thereafter, gradually decreased. How-
ever, the number of macrophages peaked at 7 days.23 
The thrombus age may be related to the response to recana-
lization treatment. In a study that measured thrombus volume 
on thin-section CT before and after IV tPA treatment, the prob-
ability of thrombus resolution decreased as the time interval 
from symptom onset to treatment increased.65 In patients with 
acute myocardial infarction, older thrombus aspirated during 
percutaneous coronary intervention was associated with im-
paired myocardial reperfusion.32 After initial thrombus forma-
tion, the thrombus is stabilized by further accumulation and 
crosslinking of fibrins by factor XIII. As a result, the thrombus 
becomes more compact and the pores become smaller. This 
causes lower penetration of tPA, which limits its fibrinolytic 
action.67,68 In addition, more neutrophils infiltrate into the 
thrombus over time, which subsequently form NETs. 
Leukocytes and NETs may be associated with resistance to IV 
tPA. Among the two scaffolds of thrombus, the fibrin mesh-
work and NETs, tPA can lyse only fibrin. As such, it is expected 
that thrombi with abundant NETs may be resistant to tPA. Sev-
eral studies have investigated whether thrombus can be lysed 
by treatment with deoxyribonuclease I (DNAse I), which can 
degrade NETs. In ex vivo studies using fresh thrombi obtained 
from stroke patients, the addition of DNAse I to tPA increased 
thrombus lysis compared to tPA alone.22,33 However, treatment 
with DNAse I alone had no thrombolytic effects.33 These find-
ings suggest that adjunctive treatment with DNAse I can po-
tentiate the effect of tPA.
Cancer stroke
Antithrombotic treatment in stroke patients with cancer may 
differ according to the underlying mechanism. Patients with 
NBTE show a very high platelet fraction in the thrombus.25 
However, patients with determinable etiologies showed histo-
logic findings of thrombus that were similar to those in pa-
tients with determined etiologies but without cancer.25 These 
findings suggest that active cancer may be a bystander in most 
patients with other obvious etiologies, such as atrial fibrillation 
and large artery atherosclerosis. In contrast, patients with a 
cryptogenic etiology had histologic findings similar to those 
with NBTE.25 NBTE is the most common etiology of stroke in 
autopsy studies of stroke patients with cancer and is suggested 
as the likely cause of stroke in many patients with cancer with 
a cryptogenic etiology.69 As such, it may be reasonable that a 
similar antithrombotic regimen is considered for stroke preven-
tion in cancer patients with NBTE and a cryptogenic etiology. 
Patients without NBTE but with other obvious etiologies may 
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be managed according to their known etiologies.
Current guidelines recommend anticoagulation with full-
dose unfractionated heparin or subcutaneous low-molecular 
heparinoid over no anticoagulation in patients with NBTE.70 
This recommendation is based on the general belief that NBTE 
is associated with coagulopathy and chronic disseminated co-
agulopathy.70,71 However, pathologic studies of cardiac vegeta-
tion and histologic findings of intracranial thrombi indicate 
that platelets play a crucial role in the development of vegeta-
tion.25,27 Patients with stroke and cancer tend to be adverse to 
receiving injection.72 In this regard, among stroke patients with 
active cancer, antiplatelet agents may be an alternative option 
for preventing recurrent stroke in patients with NBTE or those 
with a cryptogenic etiology.40 
Conclusions
Recent advances in endovascular thrombectomy have opened 
a window for looking into fresh thrombus in patients with 
acute stroke. Consequently, this has elicited new perspectives 
on the mechanism of thrombus formation from a conceptual 
idea to a visible one. However, the window is still small, and 
thrombi obtained during mechanical thrombectomy are limited 
to those that are large and retrievable. More thrombus samples 
from patients with stroke of diverse etiologies are necessary to 
gain further insight into the pathophysiologic mechanism of 
different stroke etiologies. Furthermore, the standardization of 
the histologic examination of thrombus is also necessary. 
Translational research using fresh thrombi is also encouraged. 
Nevertheless, thrombus research is promising because it may 
provide valuable information for determining the treatment 
strategy of preventing recurrence in patients with stroke. It 
may also be helpful for the development of new thrombolytic 
agents targeting other than fibrin. Addition of DNAse-1 that 
targets NETs may enhance thrombolytic effects of tPA.22,33 tPA-
resistant von Willebrand factor-rich thrombus may be effec-
tively dissolved by ADAMTS13 (a disintegrin and metallopro-
teinase with a thrombospondin type 1 motif, member 13) that 
targets von Willebrand factor.57 Saxatilin targeting multiple in-
tegrins on platelets and leukocytes may also effectively dis-
solve thrombus by disaggregating platelet-fibrin binding and 
inhibiting platelet-leukocyte interaction.73
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